The US Court of Appeals for the District of Columbia Circuit on Friday dismissed a case brought by the Federal Trade Commission against Endo Pharmaceuticals and Impax Laboratories, affirming a lower court ruling that rejected the commission’s claims that the competitor companies created an exclusionary agreement around the opioid Opana ER (oxymorphone extended release).
Impax's Generic Colesevelam Hydrochloride Receives Approval in the U.S.
Impax Inks $145M Deal With Direct Purchasers In Opana MDL
Endo International Plc and Impax Laboratories LLC will face an ordinary class action trial over allegations they schemed to block generic versions of the painkiller Opana ER, a federal judge in Chicago ruled, denying a bid for separate trials of claims by direct and indirect purchasers.
WASHINGTON, Jan. 14, 2022 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced it has entered into a License Agreement (the License Agreement) with MSN Pharmaceuticals Inc., MSN Laboratories Private Limited (together MSN) and Impax Laboratories LLC (Impax) to resolve Vanda's patent litigation against MSN regarding MSN's Abbreviated New Drug Application seeking approval of its generic version of Vanda's HETLIOZ® (tasimelteon).
The US Court of Appeals for the Fifth Circuit on Tuesday upheld the Federal Trade Commission’s ruling that generic drugmaker Impax Laboratories should be charged with antitrust violations for accepting payments worth about $100 million to delay the entry of a generic opioid for more than two years.
FTC Makes Double Reverse Payment Case Against Endo And Impax (Pink Sheet)
Impax Lab’s Generic Sevelamer Carbonate Receives Approval In US
Impax Lab’s Generic Teriflunomide Receives Tentative Approval In US